NCT00000590View on ClinicalTrials.gov

Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

September 30, 1991

Study Completion Date

December 31, 1996

Conditions
Acquired Immunodeficiency SyndromeDisease Transmission, VerticalHIV Infections
Interventions
DRUG

immunoglobulins

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00000590 - Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185) | Biotech Hunter | Biotech Hunter